164 related articles for article (PubMed ID: 28636657)
1. Novel siRNA formulation to effectively knockdown mutant p53 in osteosarcoma.
Kundu AK; Iyer SV; Chandra S; Adhikari AS; Iwakuma T; Mandal TK
PLoS One; 2017; 12(6):e0179168. PubMed ID: 28636657
[TBL] [Abstract][Full Text] [Related]
2. Theabrownin triggers DNA damage to suppress human osteosarcoma U2OS cells by activating p53 signalling pathway.
Jin W; Zhou L; Yan B; Yan L; Liu F; Tong P; Yu W; Dong X; Xie L; Zhang J; Xu Y; Li C; Yuan Q; Shan L; Efferth T
J Cell Mol Med; 2018 Sep; 22(9):4423-4436. PubMed ID: 29993186
[TBL] [Abstract][Full Text] [Related]
3. Che-1 gene silencing induces osteosarcoma cell apoptosis by inhibiting mutant p53 expression.
Liu M; Wang D; Li N
Biochem Biophys Res Commun; 2016 Apr; 473(1):168-173. PubMed ID: 27012205
[TBL] [Abstract][Full Text] [Related]
4. Activation of PTHrP-cAMP-CREB1 signaling following p53 loss is essential for osteosarcoma initiation and maintenance.
Walia MK; Ho PM; Taylor S; Ng AJ; Gupte A; Chalk AM; Zannettino AC; Martin TJ; Walkley CR
Elife; 2016 Apr; 5():. PubMed ID: 27070462
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin induces apoptosis via upregulating Wrap53 in U-2OS osteosarcoma cells.
Yuan JM; Li XD; Liu ZY; Hou GQ; Kang JH; Huang DY; Du SX
Asian Pac J Cancer Prev; 2011; 12(12):3465-9. PubMed ID: 22471498
[TBL] [Abstract][Full Text] [Related]
6. Nanoscale polysaccharide derivative as an AEG-1 siRNA carrier for effective osteosarcoma therapy.
Wang F; Pang JD; Huang LL; Wang R; Li D; Sun K; Wang LT; Zhang LM
Int J Nanomedicine; 2018; 13():857-875. PubMed ID: 29467575
[TBL] [Abstract][Full Text] [Related]
7. Interferonalpha enhances etoposide-induced apoptosis in human osteosarcoma U2OS cells by a p53-dependent pathway.
Yuan XW; Zhu XF; Liang SG; Fan Q; Chen ZX; Huang XF; Sheng PY; He AS; Yang ZB; Deng R; Feng GK; Liao WM
Life Sci; 2008 Feb; 82(7-8):393-401. PubMed ID: 18191951
[TBL] [Abstract][Full Text] [Related]
8. Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cells.
Zhu HB; Yang K; Xie YQ; Lin YW; Mao QQ; Xie LP
World J Surg Oncol; 2013 Jan; 11():22. PubMed ID: 23356234
[TBL] [Abstract][Full Text] [Related]
9. Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells.
Mizuarai S; Yamanaka K; Kotani H
Cancer Res; 2006 Jun; 66(12):6319-26. PubMed ID: 16778209
[TBL] [Abstract][Full Text] [Related]
10. LINC01116 promotes proliferation, invasion and migration of osteosarcoma cells by silencing p53 and EZH2.
Zhang ZF; Xu HH; Hu WH; Hu TY; Wang XB
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6813-6823. PubMed ID: 31486480
[TBL] [Abstract][Full Text] [Related]
11. Suppression of Estrogen Receptor Alpha Inhibits Cell Proliferation, Differentiation and Enhances the Chemosensitivity of P53-Positive U2OS Osteosarcoma Cell.
Wang JY; Chen CM; Chen CF; Wu PK; Chen WM
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681897
[TBL] [Abstract][Full Text] [Related]
12. FOXP1 drives osteosarcoma development by repressing P21 and RB transcription downstream of P53.
Li H; Han X; Yang S; Wang Y; Dong Y; Tang T
Oncogene; 2021 Apr; 40(15):2785-2802. PubMed ID: 33716296
[TBL] [Abstract][Full Text] [Related]
13. Sirtuin 7 promotes cellular survival following genomic stress by attenuation of DNA damage, SAPK activation and p53 response.
Kiran S; Oddi V; Ramakrishna G
Exp Cell Res; 2015 Feb; 331(1):123-141. PubMed ID: 25445786
[TBL] [Abstract][Full Text] [Related]
14. A systematic review of p53 as a biomarker of survival in patients with osteosarcoma.
Fu HL; Shao L; Wang Q; Jia T; Li M; Yang DP
Tumour Biol; 2013 Dec; 34(6):3817-21. PubMed ID: 24014053
[TBL] [Abstract][Full Text] [Related]
15. A Kinase-Independent Role for Cyclin-Dependent Kinase 19 in p53 Response.
Audetat KA; Galbraith MD; Odell AT; Lee T; Pandey A; Espinosa JM; Dowell RD; Taatjes DJ
Mol Cell Biol; 2017 Jul; 37(13):. PubMed ID: 28416637
[TBL] [Abstract][Full Text] [Related]
16. p53-dependent activation of microRNA-34a in response to etoposide-induced DNA damage in osteosarcoma cell lines not impaired by dominant negative p53 expression.
Novello C; Pazzaglia L; Conti A; Quattrini I; Pollino S; Perego P; Picci P; Benassi MS
PLoS One; 2014; 9(12):e114757. PubMed ID: 25490093
[TBL] [Abstract][Full Text] [Related]
17. LAMP3 plays an oncogenic role in osteosarcoma cells partially by inhibiting TP53.
Liu S; Yue J; Du W; Han J; Zhang W
Cell Mol Biol Lett; 2018; 23():33. PubMed ID: 30008754
[TBL] [Abstract][Full Text] [Related]
18. Influence of β-catenin small interfering RNA on human osteosarcoma cells.
Zhang F; Chen A; Chen J; Yu T; Guo F
J Huazhong Univ Sci Technolog Med Sci; 2011 Jun; 31(3):353-358. PubMed ID: 21671177
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-34c inversely couples the biological functions of the runt-related transcription factor RUNX2 and the tumor suppressor p53 in osteosarcoma.
van der Deen M; Taipaleenmäki H; Zhang Y; Teplyuk NM; Gupta A; Cinghu S; Shogren K; Maran A; Yaszemski MJ; Ling L; Cool SM; Leong DT; Dierkes C; Zustin J; Salto-Tellez M; Ito Y; Bae SC; Zielenska M; Squire JA; Lian JB; Stein JL; Zambetti GP; Jones SN; Galindo M; Hesse E; Stein GS; van Wijnen AJ
J Biol Chem; 2013 Jul; 288(29):21307-21319. PubMed ID: 23720736
[TBL] [Abstract][Full Text] [Related]
20. Polymeric nanoparticles for siRNA delivery and gene silencing.
Patil Y; Panyam J
Int J Pharm; 2009 Feb; 367(1-2):195-203. PubMed ID: 18940242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
